-
AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer
16 Dec 2025 22:52 GMT
… from partners AstraZeneca and Daiichi Sankyo, may now be used … in a prepared statement.
CEO and neuroscientist Dr. Iftach … .
Enhertu was discovered by Daiichi Sankyo. In 2019, prior to … FDA approval, AstraZeneca and Daiichi Sankyo began a collaboration on the …
-
<![CDATA[Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Biomarkers and Translational Oncology ]]>
16 Dec 2025 22:11 GMT
… announced a collaboration with Daiichi Sankyo to advance biomarker discovery … quot; said Brandon Suh, CEO of Lunit. "SCOPE … biomarkers. By working with Daiichi Sankyo, we are embedding … lunit-announces-collaboration-with-daiichi-sankyo-to-advance-ai-driven …
-
AstraZeneca-Daiichi Sankyo Enhertu Combo wins USFDA approval for 1st-line HER2-Positive Metastatic Breast Cancer
16 Dec 2025 19:00 GMT
… Business, and President and CEO, Daiichi Sankyo, said, “Since its … (ADC) discovered by Daiichi Sankyo and being jointly developed … commercialised by AstraZeneca and Daiichi Sankyo.
This application was … due from AstraZeneca to Daiichi Sankyo as a milestone …
-
Lunit partners with Daiichi Sankyo to advance AI-driven oncology research
16 Dec 2025 08:42 GMT
… with Japanese pharma firm Daiichi Sankyo that aims to accelerate … two oncology pipeline programmes.
Daiichi Sankyo will apply various Lunit … ," said Brandon Suh, CEO of Lunit. "SCOPE … biomarkers. By working with Daiichi Sankyo, we are embedding these …
-
Lunit partners with Daiichi Sankyo to accelerate novel cancer drug development using AI
16 Dec 2025 02:42 GMT
… the Lunit SCOPE platform into Daiichi Sankyo’s developing pipelines.
Specifically, the … .
Through these technologies, Lunit and Daiichi Sankyo aim to discover new biomarkers … drug development process," Lunit CEO Brandon Suh. "This meeting …
-
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict
04 Dec 2025 07:04 GMT
Daiichi Sankyo has emerged victorious in appeals … that laid the golden eggs,” CEO Albert Bourla said at the …
-
General Proximity and Daiichi Sankyo link on oncology
14 Nov 2025 12:28 GMT
… platform to oncology programmes.
Daiichi Sankyo entered the collaboration through its … Proximity founder and CEO Armand Cognetta stated: “Daiichi Sankyo is a leader … platform.
In January 2025, Daiichi Sankyo finalised the acquisition of intellectual …
-
Daiichi Sankyo’s Mila Tartakovsky Shares High-Performance Roadmap on CFO IQ
31 Oct 2025 13:00 GMT
… CFOs across the United States — Daiichi Sankyo’s Head of US Finance … :
Andrew B. Zezas
Publisher & CEO of CFO Intelligence
201.906 …
-
AstraZeneca CEO: 'We can absorb the impact' of drug pricing deal with Trump
07 Nov 2025 02:04 GMT
… British pharma’s revenue target, CEO Pascal Soriot said.
“We can … July letters to 17 pharma CEOs, including Soriot.
Based on the … AZ’s cancer drugs, including Daiichi Sankyo-partnered Enhertu, the BTK inhibitor …
-
<![CDATA[Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns]]>
28 Oct 2025 23:14 GMT
… the resignation of Organon CEO Kevin Ali following an …
Organon has announced that CEO Kevin Ali will resign following … will serve as interim CEO while the board initiates … currently dominated by companies like Daiichi Sankyo, AstraZeneca, and Seagen. Industry …
About
© 1995-2025